Market Overview
The global assisted reproductive technology market reached US$ 26.32 billion in 2024 and is expected to reach US$ 46.21 billion by 2033, growing at a CAGR of 6.8 % during the forecast period 2025-2033.
The global assisted reproductive technology (ART) market encompasses a variety of medical procedures and techniques designed to assist individuals and couples in achieving pregnancy when faced with infertility challenges. This market includes services such as in vitro fertilization (IVF), artificial insemination (AI), frozen embryo transfer, and other reproductive technologies that involve manipulating eggs, sperm, and embryos outside the human body.
ART refers to fertility treatments that involve handling both eggs and sperm to facilitate conception. The most common ART procedure is IVF, where eggs are retrieved from a woman's ovaries, fertilized with sperm in a laboratory setting, and then the resulting embryos are transferred back into the woman's uterus.
The global assisted reproductive technology market plays a crucial role in addressing infertility issues faced by many individuals and couples. By providing a wide array of advanced reproductive technologies, this market not only helps in achieving pregnancy but also supports the emotional and psychological aspects of fertility treatment. As awareness increases and technology evolves, the demand for ART services is expected to continue its upward trajectory. These factors have driven the global assisted reproductive technology market expansion.
Executive Summary
Market Dynamics: Drivers & Restraints
Increasing Infertility Rates
The increasing infertility rates are significantly driving the growth of the global assisted reproductive technology market and are expected to drive throughout the market forecast period. Infertility is classified as a disease of the male or female reproductive system, defined by the inability to achieve pregnancy after 12 months or more of regular unprotected sexual intercourse. This condition can lead to significant emotional distress, stigma, and financial burdens, negatively impacting individuals' mental and psychosocial well-being.
The prevalence of infertility is increasing worldwide, as per World Health Organization(WHO) data in April 2023, impacting about 1 in 6 adults, or roughly 17.5% of the adult population. Several factors contribute to this rise, including lifestyle changes, environmental influences, and medical conditions such as polycystic ovary syndrome (PCOS) and endometriosis. As a result, more individuals and couples are seeking assistance to conceive, leading to a growing demand for assisted reproductive technology (ART) services.
The report reveals that the prevalence of infertility shows minimal variation across different regions, with rates being comparable in high-, middle-, and low-income countries. Specifically, the lifetime prevalence is reported at 17.8% in high-income nations and 16.5% in low- and middle-income countries, indicating that infertility is a substantial health challenge globally.All these factors demand the global assisted reproductive technology market.
Furthermore, key players in the industry research studies and partnerships & collaborations that woulid drive this global assisted reproductive technology market growth. For instance, in May 2024, a recent global study presented at the ESMO Breast Cancer 2024 congress has confirmed the safety of Assisted Reproductive Techniques (ART) for young women with high-risk genetic mutations, particularly those with BRCA1 or BRCA2 variants, who have survived breast cancer. This pivotal research is the first to provide evidence that utilizing ART does not elevate the risk of breast cancer recurrence or negatively affect pregnancy outcomes for these patients.
Similarly, in January 2024, Calibre Scientific announced the strategic acquisitions of Microm UK Limited and Scopescreen, LLC (operating as Bioscreen), significantly enhancing its portfolio in the field of Assisted Reproductive Technologies (ART). This expansion underscores the company's dedication to improving reproductive health and testing capabilities. Moreover, the rising demand for innovative fertility preservation techniques contributes to the global assisted reproductive technology market expansion.
High Costs of Treatment
The financial burden associated with assisted reproductive technology (ART) procedures, particularly In Vitro Fertilization (IVF), presents a significant barrier for many individuals and couples seeking fertility treatment. The high costs linked to ART can discourage many from pursuing necessary treatments. In areas where insurance coverage for fertility services is limited or nonexistent, this financial strain becomes even more pronounced. Many patients find themselves responsible for covering these expenses out-of-pocket, which can lead to substantial financial hardship or even medical debt
As per Advanced Reproductive Care data in 2024, the cost of a single in vitro fertilization (IVF) cycle in the United States generally falls between $14,000 and $20,000. This estimate excludes additional expenses such as medications, essential services, and optional add-on treatments, all of which can substantially raise the total cost. Thus, the above factors could be limiting the global assisted reproductive technology market's potential growth.
For more details on this report – Request for Sample
Segment Analysis
The global assisted reproductive technology market is segmented based on product type, technology, end-user, and region.
Technology:
The in vitro fertilization (IVF) segment is expected to dominate the global assisted reproductive technology market share
The in vitro fertilization (IVF) segment holds a major portion of the global assisted reproductive technology market share and is expected to continue to hold a significant portion of the global assisted reproductive technology market share during the forecast period.
The in vitro fertilization (IVF) segment is a critical component of the global assisted reproductive technology (art) market, addressing infertility challenges faced by individuals and couples around the world. this segment encompasses various procedures aimed at facilitating conception through the fertilization of eggs outside the human body.
A notable rise in infertility rates globally, currently affecting about 17.5% of adults, serves as a major driver for the IVF segment. Contributing factors include lifestyle changes, medical conditions such as Polycystic Ovary Syndrome (PCOS) and endometriosis, and trends toward delayed parenthood. Innovations in reproductive technologies, including improved embryo selection techniques and non-invasive genetic testing methods, have enhanced success rates in IVF treatments, making them more attractive to prospective parents.
Furthermore, key players in the industry innovative launches that would propel this segment growth in the global assisted reproductive technology market. For instance, in July 2024, Cook Medical has announced its plan to sell its Reproductive Health business, which includes its in vitro fertilization (IVF) and assisted reproductive technology (ART) portfolios, to the private equity firm Astorg. This decision is part of Cook Medical's strategy to streamline its operations and concentrate on core growth areas.
Also, in September 2024, MGM Healthcare launched the Varam IVF Centre, a dedicated facility for In Vitro Fertilization (IVF) services, located on the sixth floor of its hospital in Aminjikarai, Chennai. This new center aims to provide advanced fertility treatments and personalized care by utilizing the latest technologies and bringing together a team of renowned specialists. These factors have solidified the segment's position in the global assisted reproductive technology market.
Geographical Analysis
North America is expected to hold a significant position in the global assisted reproductive technology market share
North America holds a substantial position in the global assisted reproductive technology market and is expected to hold most of the market share. The prevalence of infertility in North America is a significant factor propelling market growth. Approximately 17.5% of adults globally experience infertility, a trend mirrored in the United States. Recent data from the Census Bureau indicated a 43% decline in fertility rates among women aged 20-24, highlighting the growing challenges many faces in conceiving. This increase in infertility rates has led to a heightened demand for ART services.
North America, particularly the United States, has a well-established healthcare infrastructure that supports advanced reproductive technologies. With nearly 500 fertility clinics operating across the country, patients have access to a wide range of ART services. This extensive network enhances accessibility and contributes to the overall growth of the market. Continuous innovations in ART technologies, such as enhanced embryo culture techniques and genetic screening methods (e.g., Preimplantation Genetic Testing), have improved success rates for procedures like IVF. The introduction of new products and technologies further enhances the market's growth potential.
Furthermore, in this region major of key players presence and innovative launches that would drive this global assisted reproductive technology market growth. For instance, in March 2024, in New York, TMRW Life Sciences introduced CryoLink, a digital management system specifically designed for fertility clinics to enhance the storage and tracking of frozen eggs and embryos. This innovative workstation allows clinics to quickly and efficiently upgrade their existing storage processes, providing a modern and secure solution for managing frozen specimen inventories.
Also, in October 2024, Cook Medical introduced the NestVT Vitrification Device for in-vitro fertilization (IVF) in the United States. This innovative device is specifically engineered to ensure the secure handling of embryos and oocytes during vitrification, cryo-storage, and relocation processes. The launch of NestVT is part of Cook Medical's broader initiative to establish itself as a trusted partner in IVF, offering comprehensive support through simulation training and educational resources to enhance the entire IVF experience. Thus, the above factors are consolidating the region's position as a dominant force in the global assisted reproductive technology market.
Asia Pacific is growing at the fastest pace in the global assisted reproductive technology market share
Asia Pacific holds the fastest pace in the global assisted reproductive technology market and is expected to hold most of the market share. Infertility is a pressing global issue, impacting around 17.5% of adults. This widespread challenge is significantly driving the demand for assisted reproductive technology (ART) services. Key factors contributing to rising infertility include delayed childbearing and various lifestyle changes that adversely affect reproductive health.
Increased funding from governments and favorable regulatory frameworks are enhancing the accessibility of ART services. This support is crucial for facilitating market growth and ensuring that a wider population can benefit from these technologies. Innovations in ART procedures, such as pre-implantation genetic testing (PGT), the integration of artificial intelligence, and improved techniques for fertility preservation, are not only boosting success rates but also attracting more patients seeking effective solutions.
Assisted reproductive technology (ART) encompasses a variety of methods designed to facilitate pregnancy by manipulating sperm and egg cells outside the human body, followed by the transfer of embryos into a woman's reproductive system. In India, the practice of ART is governed by the Assisted Reproductive Technology (Regulation) Act, 2021, which was enacted to create a regulatory framework for ART clinics and banks. This framework aims to ensure ethical practices and enhance the safety and quality of care provided to patients seeking fertility treatments.
The Health Ministry of India implemented the Assisted Reproductive Technology (ART) Regulations in 2023 to enhance the safety and quality of medical care for both donors and patients. While these regulations aim to create a more ethical framework for ART practices, industry insiders have reported that the new provisions have led to higher medical costs and present challenges for doctors and couples seeking ART services, largely due to a reduced availability of donors.
Furthermore, key players in the region, awareness campaign and innovative launches that would drive this global assisted reproductive technology market growth. For instance, in July 2023, China launched a comprehensive campaign aimed at addressing illegal activities linked to Assisted Reproductive Technologies (ART), such as the sale and purchase of sperm and eggs, as well as surrogacy practices. This initiative, set to last for six months, seeks to mitigate rising public concerns regarding the ethical and legal ramifications of these practices.
Also, in July 2024, Nikon Corporation is set to launch the ECLIPSE Ti2-I Motorized Inverted Microscope tailored specifically for Intracytoplasmic Sperm Injection (ICSI) and Intracytoplasmic Morphologically Selected Sperm Injection (IMSI), both of which are critical techniques in micro-insemination. This advanced microscope allows for automatic control of settings through user-friendly buttons and a conveniently positioned touch screen, resulting in a reduction of approximately 75% in the steps required for operation. Additionally, the ECLIPSE Ti2-I features an alert function and provides a bright, clear field of view, supporting precise and accurate operations during fertility treatments. Thus, the above factors are consolidating the region's position as the fastest-growing force in the global assisted reproductive technology market.
Competitive Landscape
The major global players in the assisted reproductive technology market include Ferring B.V., Hamilton Thorne, Merck KGaA, CooperSurgical Fertility Solutions, European Sperm Bank, Bloom Fertility Centre., Vitrolife, FUJIFILM Irvine Scientific., NidaCon International AB., and Microm UK Limited among others.
Key Developments
- In November 2024, SpOvum Technologies introduced an innovative AI-driven platform called ARTGPT, aimed at improving patient support in Assisted Reproductive Technology (ART). This innovative platform is designed to deliver personalized information that addresses individual ART-related concerns, ensuring users receive accurate and reliable responses sourced from indexed medical guides.
- In March 2023, ART Fertility Clinics launched its inaugural television advertisement featuring a woman who sought treatment after struggling to conceive naturally. This ad emphasizes the clinic's three core trust factors: Treatment, Technology, and Transparency, which have collectively contributed to a notable pregnancy success rate of 70%.
| Metrics | Details | |
| CAGR | 6.8% | |
| Market Size Available for Years | 2023-2033 | |
| Estimation Forecast Period | 2025-2033 | |
| Revenue Units | Value (US$ Bn) | |
| Segments Covered | Product Type | Instruments, Accessories & Disposables, Reagents & Media, Others |
| Technology | In Vitro Fertilization (IVF), Artificial Insemination (AI), Intracytoplasmic Sperm Injection (ICSI), Cryopreservation, Preimplantation Genetic Testing (PGT), Others | |
| End-User | Hospitals, Fertility Clinics, Others | |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa | |
Why Purchase the Report?
- Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
- Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
- Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
- Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
- Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
- Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
- Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
- Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
- Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
- Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
- Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
- Post-market Surveillance: Uses post-market data to enhance product safety and access.
- Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.
The global assisted reproductive technology market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.
Target Audience 2023
- Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
- Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
- Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
- Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
- Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
- Supply Chain: Distribution and Supply Chain Managers.
- Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
- Academic & Research: Academic Institutions.
